Mohammad Azhar

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 5 papers. Top paper: “Momelotinib is a highly potent inhibitor of FLT3-mutant AML”.

Momelotinib is a highly potent inhibitor of FLT3-mutant AML

Blood Advances(2021)10.1182/bloodadvances.2021004611

N/A

0DataRank · unranked

19 citations

Zachary Kincaid, Meenu Kesarwani, Arhama Ahmed, Mark Wunderlich, Tahir Latif +3 more

Momelotinib is a highly potent inhibitor of FLT3-mutant AML

bioRxiv (Cold Spring Harbor Laboratory)(2021)10.1101/2021.03.18.436047

N/A

0DataRank · unranked

2 citations

Zachary Kincaid, Meenu Kesarwani, Tahir Latif, Daniel T. Starczynowski, Mohammad Azam +1 more

Rational polypharmacological targeting of FLT3, JAK2, ABL, and ERK1 suppresses the adaptive resistance to FLT3 inhibitors in AML

Blood Advances(2022)10.1182/bloodadvances.2022007486

N/A

0DataRank · unranked

8 citations

Zachary Kincaid, Meenu Kesarwani, Jacob Menke, Joshua Schwieterman, Sekhu Ansari +11 more

MAPK-negative feedback regulation confers dependence to JAK2V617F signaling

Leukemia(2023)10.1038/s41375-023-01959-0

N/A

0DataRank · unranked

5 citations

Zachary Kincaid, Mohammad Azhar, Jacob Menke, Joshua Schwieterman, Sekhu Ansari +6 more

Enhanced MAPK signaling induced by CSF3R mutants confers dependence to DUSP1 for leukemic transformation

Blood Advances(2024)10.1182/bloodadvances.2023010830

N/A

0DataRank · unranked

4 citations

Zachary Kincaid, Mohammad Azhar, Mohammad Azam, Meenu Kesarwani